乳腺导管原位癌全乳放疗后瘤床加量照射与局部控制的关联
该回顾性汇总分析纳入10家学术机构4131例纯导管原位癌患者,比较全乳放疗后加量与不加量瘤床照射的同侧乳腺肿瘤复发。中位随访9年,加量组同侧乳腺肿瘤复发风险显著低于不加量组(HR 0.73,95%CI 0.57-0.94,P=0.01),多因素分析后仍显著(HR 0.68,95%CI 0.50-0.91,P=0.01)。作者认为经医患共同讨论后可考虑加量照射。
要点
- 全乳放疗后加量组同侧乳腺肿瘤复发风险显著低于不加量组(HR 0.73,95%CI 0.57-0.94,P=0.01)。
- 多因素分析校正混杂因素后,加量仍与同侧乳腺肿瘤复发降低显著相关(HR 0.68,95%CI 0.50-0.91,P=0.01)。
- 作者认为经患者与放疗科医生共同讨论后可考虑对瘤床加量以提供额外增量获益。
核心结论
- 该患者水平分析提示,放疗加量在所有导管原位癌年龄组中均带来同侧乳腺肿瘤复发降低的统计学显著获益,与浸润性乳腺癌中所见相似。
- 作者认为经患者与放疗科医生共同讨论后可考虑对导管原位癌瘤床加量,以在降低同侧乳腺肿瘤复发方面提供额外增量获益。
研究设计与样本
- 回顾性分析汇总美国、加拿大和法国10家学术机构1980年1月1日至2010年12月31日的去标识化患者水平数据。
- 纳入新诊断纯导管原位癌(无微浸润)、接受保乳手术并接受全乳放疗加或不加瘤床加量、且随访至少5年的患者。
- 样本量计算(加量组与不加量组比例2:1;α=0.05;把握度80%)估计需2982例以检测至少3%的差异。
- 最终分析纳入4131例患者(加量组2661例,不加量组1470例),中位随访9年,中位加量剂量14 Gy。
- 数据收集于2011年7月至2014年2月,分析于2014年3月至2015年8月。
主要发现
- 全队列中,加量组同侧乳腺肿瘤复发风险显著低于不加量组(HR 0.73,95%CI 0.57-0.94,P=0.01)。
- 加量组与不加量组无同侧乳腺肿瘤复发生存率:5年97.1%(95%CI 0.96-0.98)vs 96.3%(95%CI 0.95-0.97),10年94.1%(95%CI 0.93-0.95)vs 92.5%(95%CI 0.91-0.94),15年91.6%(95%CI 0.90-0.93)vs 88.0%(95%CI 0.85-0.91)。
- 多因素分析校正混杂因素后,加量仍与同侧乳腺肿瘤复发降低显著相关(与不加量相比HR 0.68,95%CI 0.50-0.91,P=0.01),且独立于年龄和他莫昔芬柠檬酸盐使用。
- 切缘阳性、雌激素受体状态未知和粉刺样坏死的患者更可能接受放疗加量。
临床怎么用
- 作者认为,经患者与其放疗科医生共同讨论后,可考虑对导管原位癌瘤床进行放疗加量,以在降低同侧乳腺肿瘤复发方面提供额外增量获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The use of a radiotherapy (RT) boost to the tumor bed after whole-breast RT (WBRT) for ductal carcinoma in situ (DCIS) is largely extrapolated from invasive cancer data, but robust evidence specific to DCIS is lacking. OBJECTIVE: To compare ipsilateral breast tumor recurrence (IBTR) in women with DCIS treated with vs without the RT boost after breast-conserving surgery and WBRT. DESIGN, SETTING, AND PARTICIPANTS: This retrospective analysis pooled deidentified patient-level data from 10 academic institutions in the United States, Canada, and France from January 1, 1980, through December 31, 2010. All patients had newly diagnosed pure DCIS (no microinvasion), underwent breast-conserving surgery, and received WBRT with or without the boost with a minimum of 5 years of follow-up required for inclusion in the analysis. Given the limited events after WBRT, an a priori power analysis was conducted to estimate the DCIS sample size needed to detect the anticipated benefit of the boost. Data were uniformly recoded at the host institution and underwent primary and secondary reviews before analysis. Sample size calculations (ratio of patients who received the boost dose to those who did not, 2:1; α = .05; power = 80%) estimated that 2982 cases were needed to detect a difference of at least 3%. The final analysis included 4131 patients (2661 in the boost group and 1470 in the no-boost group) with a median follow-up of 9 years and media boost dose of 14 Gy. Data were collected from July 2011 through February 2014 and analyzed from March 2014 through August 2015. INTERVENTIONS: Radiotherapy boost vs no boost. MAIN OUTCOMES AND MEASURES: Ipsilateral breast tumor recurrence. RESULTS: The analysis included 4131 patients (median [SD] age, 56.1 [10.9] years; range, 24-88 years). Patients with positive margins, unknown estrogen receptor status, and comedo necrosis were more likely to have received an RT boost. For the entire cohort, the boost was significantly associated with lower IBTR (hazard ratio [HR], 0.73; 95% CI, 0.57-0.94; P = .01) and with IBTR-free survival (boost vs no-boost groups) of 97.1% (95% CI, 0.96-0.98) vs 96.3% (95% CI, 0.95-0.97) at 5 years, 94.1% (95% CI, 0.93-0.95) vs 92.5% (95% CI, 0.91-0.94) at 10 years, and 91.6% (95% CI, 0.90-0.93) vs 88.0% (95% CI, 0.85-0.91) at 15 years. On multivariable analysis accounting for confounding factors, the boost remained significantly associated with reduced IBTR (HR compared with no boost, 0.68; 95% CI, 0.50-0.91; P = .01) independent of age and tamoxifen citrate use. CONCLUSIONS AND RELEVANCE: This patient-level analysis suggests that the RT boost confers a statistically significant benefit in decreasing IBTR across all DCIS age groups, similar to that seen in patients with invasive breast cancer. These findings suggest that a DCIS RT boost to the tumor bed could be considered to provide an added incremental benefit in decreasing IBTR after a shared discussion between the patient and her radiation oncologist.
引用
- Moran MS, Zhao Y, Ma S, et al. Association of Radiotherapy Boost for Ductal Carcinoma In Situ With Local Control After Whole-Breast Radiotherapy. JAMA Oncol. 2017. PMID: 28358936. doi:10.1001/jamaoncol.2016.6948
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。